Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
11 mars 2022 16h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® (aducanumab-avwa)...
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
07 févr. 2022 16h05 HE
|
Biogen Inc.
CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization...
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
01 févr. 2022 07h30 HE
|
Biogen Inc.
Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic areas CAMBRIDGE, Mass., Feb. 01,...
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
31 janv. 2022 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen’s Board of Directors, effective at the time...
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
27 janv. 2022 18h50 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that they have entered into an agreement whereby Samsung Biologics will acquire Biogen’s equity stake in...
Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM®
27 janv. 2022 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced additional details about the Phase 4 post-marketing confirmatory...
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
04 janv. 2022 07h34 HE
|
Biogen Inc.
BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE,...
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
22 déc. 2021 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical...
Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease
20 déc. 2021 07h00 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM®...
Update on Regulatory Submission for Aducanumab in the European Union
17 déc. 2021 06h44 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for Medicinal Products for Human Use (CHMP) of...